VKTX Reports Q3 as Shorts Hold and Options Lean Bullish

Viking Therapeutics heads into its Q3 earnings print today with a stock down 30% over the past month, shorts sitting at 22.6% of the float, and options traders still leaning toward calls rather than puts.

The short position is substantial but has been edging lower this week. Short interest fell from roughly 26.2 million shares on October 21 to 25.5 million by October 27, a 2% week-on-week decline, though it remains 15% above where it was a month ago. That month-long build tracks the stock's 30% slide from above $35 and reflects genuine bear conviction around the obesity market differentiation question. The ORTEX short score has held in a narrow band around 72 to 73 for the past two weeks, down modestly from the 73.8 reading seen on October 14 but still firmly elevated. Borrow cost has drifted back to 0.48%, down sharply from the 0.78 to 0.88% range that prevailed through most of October, and availability has opened up to 84%, meaning there are roughly 54 million shares still available to lend against the 25.5 million already borrowed. The borrow market is loose, not squeezed, and new shorts face no mechanical friction getting on.

Options traders are leaning the other way. The put/call ratio is at 0.22, slightly below its 20-day average of 0.23 and still close to the lower end of the past year's range. The 52-week low is 0.16 and the high is 0.54. With the ratio sitting comfortably below its mean, call volume is dominating. That mirrors what the October 21 note described, and the positioning has not shifted materially since. The two signals are pulling in opposite directions: a large and recently expanding short book versus an options market that has consistently favoured upside.

The Street lines up firmly behind the stock despite the drawdown. Every recent analyst action in the past several weeks has been a buy or overweight, with targets ranging from $65 at JP Morgan to $125 at BTIG. UBS initiated coverage earlier this month with a buy and a $94 target. Canaccord trimmed its target from $114 to $106 on October 20 but maintained its buy. The consensus mean target is $95.05, against a stock trading at $24.89, a gap that reflects how far and fast the stock has fallen rather than any fundamental re-rating of the bullish case. The analyst recommendation differential factor ranks in the 93rd percentile of the ORTEX universe, the single highest factor score on the sheet. The bear case centres on concentration risk in VK2735, the Ligand licensing overhang which could reach $75 million per indication in milestones plus royalties, and the difficulty of carving out pricing power in a market that Eli Lilly already dominates. The bull case rests on VK2735's phase 2 data showing up to 21.7% weight loss by week 33 with no plateau, a clean GI tolerability profile, and a $603 million cash balance expected to fund operations into 2028.

Institutional positioning is relatively stable. FMR and BlackRock are the two largest holders, each around 5 to 5.4% of shares as last reported through August and September respectively. State Street added just over 1.2 million shares in its most recently reported quarter. Brian Lian, the CEO, sold 148,517 shares at roughly $33.32 on July 29, a clean open-market sale not under a 10b5-1 plan, worth about $4.9 million. The CFO and COO also sold on the same day. All three sales occurred on the day of the prior quarter's earnings release, a pattern worth noting for context. No insider buying of open-market shares has been reported since the CCO purchased 4,475 shares in March.

The past two earnings releases have produced negative next-day moves: down 3.3% in October and down 2.2% in July. Both five-day reactions were also modestly negative. Wikipedia page views registered a z-score of 3.4 as of October 19, a significant spike in retail attention by the stock's own history, which lines up with the earnings timing rather than any new public data.

The retail attention spike and the elevated short base mean today's print is being watched from multiple directions. Whether the VK2735 data update and cash burn commentary shifts the bear conviction that built through October is the one number to follow after the close.